CureVac to Present at Upcoming International Investor Conferences

TÜBINGEN, Germany, May 19, 2017 – CureVac AG, the most clinically ad-vanced mRNA company, today announced that the company will present at two upcoming international investor conferences: UBS 2017 Global Healthcare Conference in New York, NY; and Bio€quity Europe in Paris, France.  
Executives from CureVac will provide an overview of the company’s business, industry-leading mRNA technology platform, and clinical-stage product pipeline during each presentation and will be available to participate in one-on-one meet-ings with investors who are registered to attend each conference.

UBS 2017 Global Healthcare Conference
Pierre Kermula, Chief Financial Officer
Monday, May 22, 2017
2:30 – 3:00 pm, ET
Grand Hyatt, New York, NY – Ballroom IV

Bio€quity Europe
Dr. Franz-Werner Haas, Chief Corporate Officer
Monday, May 22, 2017
3:40 – 4:00 pm, CET
Marriott Rive Gauche, Paris, France– Forum EF, Level -1

Download press release as PDF file.

Your contact

Verena Lauterbach
Senior Manager Communications
T: +49 7071 9883 1756
contact via e-mail